ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
19 janv. 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
14 nov. 2022 18h20 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
07 nov. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
02 nov. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
05 oct. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
09 sept. 2022 08h30 HE
|
ABVC BioPharma, Inc.
New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
ABVC BioPharma Provides Vitargus® Update
18 août 2022 08h30 HE
|
ABVC BioPharma, Inc.
Phase II Vitargus® Clinical Trial Receives Local Ethics Committee Approval in Thailand FREMONT, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
15 août 2022 17h48 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Provides Vitargus® Update
02 août 2022 08h30 HE
|
ABVC BioPharma, Inc.
Phase II Vitargus® Clinical Study Protocol Receives Local Ethics Committee Approval FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
Zacks Places Share Value of ABVC BioPharma at $9.50
06 juil. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...